Answers are grounded in this paper and cite their sources.
Background/aims To assess real-world outcomes of Preserflo MicroShunt (PMS) implantation combined with primary intraluminal ripcord (stent) insertion using a 9–0 polypropylene suture. Methods A consecutive retrospective cohort study including all adult patients undergoing PMS implantation with primary intraluminal stenting at a single centre between September 2021 and May 2024. Participants were followed for a minimum of 6 months and up to 18 months postoperatively. Results Thirty-eight eyes of 35 patients were analysed. The overall surgical success rate at 6 months was 89.5% (complete success 81.6%; qualified success 7.9%). Mean intraocular pressure (IOP) decreased significantly from baseline at all visits, with mean percentage reductions of 40.1%, 34.1% and 30% at 6, 12 and 18 months, respectively (all p<0.001). Glaucoma medication use also decreased significantly at all timepoints (all p<0.001), averaging 0.12±0.48 medications at 6 months. Intraluminal stents were removed in 63.2% of eyes at a median of 84 days post-surgery (IQR 35–124). Numerical hypotony (IOP <6 mm Hg without visual or anatomical sequelae) occurred in six eyes (15.8%), all resolving with conservative management. Conclusions Primary intraluminal stenting with a 9–0 prolene suture effectively prevented clinically significant hypotony while maintaining stable IOP and reduced medication dependence at 6 months. These outcomes remained stable in the subset of patients followed for up to 18 months after PMS implantation.
No takes yet. Share an insight, caveat, or question.
Mendel et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: